在胃癌中,LSD1是一种可向的漏洞,它含有TP53框架转移突变
Suzeng Wang1,2,3, Chunyu Yang2,3, Junhui Tang2,3
1Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi, 214062, Jiangsu, China.
Clinical epigenetics
|February 18, 2025
概括
没有核定位序列 (NLS) 的TP53框架转移突变驱动激进的胃癌. 抑制剂GSK690通过阻断LSD1-CCNA2信号来准这种亚型,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- TP53突变与侵袭性胃癌 (GC) 和化学抵抗有关.
- 框架转移突变是GC中第二常见的TP53突变类型,但它们的影响和向治疗仍然不清楚.
- 基斯甲基化在TP53突变癌症中起作用,抑制剂显示出治疗潜力.
研究的目的:
- 为了研究TP53框架转移突变在胃癌中的后果.
- 为具有特定TP53突变的GC患者确定向疗法.
- 探索质子甲基化在TP53突变GC中的作用.
主要方法:
- 对基因组脱甲基酶抑制剂的查与各种TP53突变的GC细胞系.
- 在体外和体内评估GSK690在TP53框架转移GC模型中的疗效.
- 双化酶试验和ChIP-qPCR,以阐明涉及p53,LSD1和CCNA2.2的分子机制.
主要成果:
- GSK690是一种氨酸特异性去甲基酶1 (LSD1) 抑制剂,可选择性地抑制具有缺乏核定位序列的TP53移突变 (TP53移NLS) 的GC细胞,其中包括GC中89%的这种突变.
- 通过LSD1-CCNA2轴,GSK690诱导了G1/S细胞循环停止,在体外和体内都显示出特定的抑制.
- 发现p53转录抑制活动的丧失驱动了TP53 Frameshift NLS癌细胞中的LSD1上调.
结论:
- 由于p53的核局部化缺陷,导致TP53的LSD1表达在GC中增加.
- 在这种GC亚型中,GSK690通过向异常的LSD1-CCNA2信号通路,有效地抑制细胞周期进展和瘤生长.
- 这项研究为患有TP53 Frameshift NLS突变的胃癌患者提供了精确的治疗策略.
更多相关视频
03:05Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
956
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
03:18Non-LTR Retrotransposons
11.3K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.3K